Get started
MODERNA INC CEDEAR EACH 19 REP 1 ORDMODERNA INC CEDEAR EACH 19 REP 1 ORDMODERNA INC CEDEAR EACH 19 REP 1 ORD

MODERNA INC CEDEAR EACH 19 REP 1 ORD

No trades
See on Supercharts
Overview Financials News
Ideas
Minds Technicals

MRNA trade ideas

MRNA, bound for exponential growth! MASSIVE RISE in 12 months!MRNA went parabolic during the COVID era reaching as high as 500. Then it went on a cooling down mode coincindingly when the pandemic has started fading. Now a BIG SHIFT has been registered based on its long term data metrics. This is massive because it took the stock 2.5 years to make this happen again. A breakout has been spotted on its long term trend. We got a break in structure confirming that major position takers has started piling up already for that new round of massive growth prospect. Histogram registered it's elusive 'hop' over the line already. First time in ages. The most awaited confirmation is ON. Best seeding season is NOW. This will be an investors' gem. Spotted at 140.0 Interim target at 300.0 Long term: 500. TAYOR.
NASDAQ:MRNALong
by JSAL
1
Pharmacies are very over bookedThis has nothing to do with politics, shut downs or any misinformation on COV1D. I went to fill my Adderall prescription at my local pharmacy and it took 30 minutes. I have never seen a bigger line in Safeway. I proceeded to ask the pharmacist, why are you so busy and when did it start? She responded with "vaccines are why, there is only MRNA to choose from". This is purely based on seasonal demand and we should be hearing more about this in the news within the next couple of months. Thecnical reasons: RSI and MACD are ticking up on the larger time frames. Very over sold.
NASDAQ:MRNALong
by LeapTrades
1
MRNA Taking Profit, Watching for a add LONG after a pullback.MRNA has been on fire since the earnings beat 4 weeks ago and has added 60% to its market cap in the past three months. It compares well with NVAX which as a prior penny stock has more volatility and upside potential. In general vaccine stocks are performing well as COVID RSV and influenza vaccines are active in research are Viral Hepatitis vaccine enhancements and the drive for an HIV vaccine. MRNA is strong and perhaps becoming overbought. The mass index indicator has topped and maybe falling to the trigger line. I will take a one- third partial off my position here and wait for a pullback with reversal to add back into the position at a lower price. The tandem of MRNA and NVAX has been very profitable for me. Careful in trade management will help me keep it that way.
NASDAQ:MRNALong
by AwesomeAvani
$MRNA. Ready for a boost? Today the markets took a toll but caught a bounce by the end of market close. A few sectors did hold up well structure wise. Those sectors were AMEX:XLV and $XLC. With this in mind, a flow order came in today for $MRNA. NASDAQ:MRNA trades within the AMEX:XLV sector (Healthcare) so automatically this caught my eye. This order is a $155 call expiring 6/7. With the healthcare holding up and this order is bullish on mrna it seems like we will long this ticker into 6/7. Price Action & Zones: We are in a trending parallel right now (buyers getting in control). Within the parallel it seems we took out the buyers and the sellers and then price came back into the range. Expected range is $160.84 for the upside and $134.80 for the downside, liquidity will lay at these levels. Watering hole from $152.97 - $154.01. Entry/Add/Target/Exit: Entry is on 50-60% discount or a gap up and hold for a while, maybe a chop and a C leg to follow. The add time is market close (if we enter market open). Target is when we are up 50-70% of our contracts value (hold a runner). Exit is if we lose upwards momentum and tank past 60% discount.
NASDAQ:MRNALong
by OakFDom
MRNA A Promising Investment Opportunity Moderna, Inc., a pioneering biotechnology firm, has been at the forefront of mRNA technology, revolutionizing the way we approach vaccines and therapeutics. As of now, Moderna's stock exhibits strong momentum, capturing the attention of investors and analysts alike. ### Investment Thesis **Strong Momentum:** Moderna's stock has shown impressive performance, underpinned by robust financials and the successful rollout of its COVID-19 vaccine. The company's ability to rapidly develop and commercialize its mRNA vaccine has not only generated significant revenue but has also demonstrated the potential of its mRNA platform for other therapies. **Target Prices:** Analyzing the weekly trading frame, Moderna shows potential to reach target prices of $138 and $162. These targets are based on technical analysis, considering the stock’s current trajectory and market conditions. The momentum is strong, and if it continues, reaching these levels could be plausible in the forthcoming period. **Stop Loss Consideration:** To manage risk, a stop loss at $94 is advisable. This level is strategically placed to protect investments from unexpected market volatilities while allowing room for the stock to fluctuate and realize its potential. ### Market Position and Future Prospects Moderna’s success with its COVID-19 vaccine has provided a substantial financial cushion and has accelerated its research and development pipeline. The company is actively expanding its portfolio, including vaccines for influenza, HIV, and other diseases, which could be game-changers in the pharmaceutical industry. ### Conclusion With a strong market position, promising pipeline, and ongoing positive momentum, Moderna (MRNA) represents a compelling investment opportunity. Targeting $138 and $162 with a strategic stop loss at $94 on the weekly frame, investors could potentially capitalize on Moderna’s innovative approach to medicine and its growing impact on global health.
NASDAQ:MRNALong
by DrSaud1
Moderna Breaks Out 12.68% For The First Time In A YearModerna ( NASDAQ:MRNA ) stock broke out for the first time in a year after beating Wall Street's first-quarter expectations as its second potential approval looms. The company hopes to win Food and Drug Administration approval for its RSV vaccine, which causes cold-like symptoms in most people but can be serious or deadly in babies and older adults. The FDA is due to make its decision on Moderna's shot in less than two weeks. Moderna ( NASDAQ:MRNA ) hopes to launch its vaccine for older adults this fall. If approved, this would be Moderna's second commercial product behind its Covid vaccine. Moderna's Covid vaccine sales plummeted nearly 91% to $167 million during the first quarter, but handily beat analysts' forecast for $93 million. The European Union plans to buy up to 36 million doses of its Covid vaccine each year for at least four years. The company expects "higher vaccination uptake" in the U.S. if its updated Covid vaccine is available in time with the seasonal flu shot. From a financial standpoint, Moderna ( NASDAQ:MRNA ) is retaining its outlook for the year. The company expects to notch $4 billion in sales of its respiratory vaccines. That will be weighted to the back half of the year with less than $300 million in sales projected for the first half of 2024. Moderna ( NASDAQ:MRNA ) stock analysts project $4.19 billion in full-year revenue, including $4.06 billion in sales from the company's products. The RSV vaccine could be a big moneymaker for Moderna ( NASDAQ:MRNA ). Pfizer and GSK launched their RSV shots for older adults last year, with Abrysvo and Arexvy generating $145 million and $228 million in sales respectively. Moderna stock analysts already expect some sales of Moderna's product — $10 million in the June quarter, according to FactSet. Moderna is ( NASDAQ:MRNA ) also planning to work with U.S. regulators on the timing of its next Covid vaccine. Officials will choose the next variant to target in booster shots on May 16, then it will be off to the races, so to speak, to run testing for Moderna's updated shot. Moderna's goal is to launch the Covid booster shot in timing with the fall flu vaccine campaign.
NASDAQ:MRNALong
by DEXWireNews
Moderna's Vaccine Spark Hope in Head and Neck Cancer TreatmentIn a significant breakthrough for cancer treatment, Moderna's ( NASDAQ:MRNA ) individualized cancer vaccine, developed in collaboration with Merck, has shown remarkable promise in an early-stage trial targeting head and neck cancer. The encouraging results have ignited a surge in Moderna's stock price and injected fresh optimism into the field of oncology research. The vaccine, mRNA-4157, aims to train the immune system to identify and combat specific mutations present in cancer cells, representing a pioneering approach in personalized cancer therapy. Following its success in treating melanoma, the vaccine has now demonstrated positive responses in patients with head and neck squamous cell carcinoma, a challenging form of cancer. Data presented at the American Association for Cancer Research Annual Meeting showcased the vaccine's efficacy when administered in combination with Merck's Keytruda. The study, involving 22 patients, revealed promising clinical responses, including instances of complete remission. Notably, the combination therapy not only triggered robust immune responses but also exhibited favorable safety profiles, marking a significant milestone in cancer immunotherapy. Jefferies analyst Michael Yee lauded the results, highlighting the potential of Moderna's therapy platform to transcend melanoma and extend its benefits to other cancer types. The data underscore the transformative potential of mRNA-based vaccines in revolutionizing cancer treatment paradigms and offering new hope to patients grappling with advanced malignancies. The positive outcome has bolstered investor confidence in Moderna ( NASDAQ:MRNA ), propelling its shares to a three-month high. This uptrend reflects renewed enthusiasm for the biotech firm's diverse pipeline, which includes groundbreaking vaccines targeting respiratory syncytial virus and other infectious diseases, alongside innovative cancer therapies. Looking ahead, Moderna's collaboration with Merck signals a concerted effort to advance the development of cancer immunotherapies. The initiation of a Phase 3 trial targeting lung cancer underscores the commitment to translating promising preclinical data into clinically meaningful outcomes, to deliver transformative therapies to patients in need. As Moderna ( NASDAQ:MRNA ) continues to pioneer the frontier of mRNA-based therapeutics, the recent success of its cancer vaccine heralds a new era in precision medicine. With further advancements and clinical validations, this innovative approach holds the potential to reshape the landscape of cancer treatment and offer renewed hope for patients battling this devastating disease.
NASDAQ:MRNALong
by DEXWireNews
Given a breakout of this area we should see a great climbHere's a small interesting history: In the late 19th century, stock trading took place through an archaic system of handwritten ledger entries and paper shares that had to be physically transported between offices. This cumbersome process led to frequent errors and delays. In 1887, a group of Wall Street clerks devised a more efficient method by setting up networks of pneumatic tubes to rapidly shuttle documents between brokerage houses and the exchange floor. This "mail tube" system, patented in 1892, could propel cylindrical cartridges containing stock certificates and instructions through a maze of underground pipes at speeds of up to 35 mph - a revolutionary breakthrough for finance at the time. The pneumatic tube network grew to span 27 miles of subterranean tubing and remained an integral part of Wall Street trading until the 1960s when it was replaced by digital tickertapes and information networks.
NASDAQ:MRNALong
by Borrai
$MRNA Bearish to Bullish Reversal NASDAQ:MRNA Bearish to Bullish Reversal A "Bearish to Bullish Reversal" in technical analysis for NASDAQ:MRNA suggests a shift in the stock's price movement pattern from a downward trend (bearish) to an upward trend (bullish). This reversal typically occurs after a period of decline, indicating that the stock may be transitioning from a bearish phase to a bullish phase. It could signify a potential turning point in market sentiment, with investors becoming more optimistic about the stock's future prospects. Traders often look for confirmation signals to validate this reversal, such as increased trading volume or positive fundamental developments in the company.
NASDAQ:MRNALong
by AlgoTradeAlert
Moderna Surge as it Dives into Promising Cancer Vaccine TrialsModerna ( NASDAQ:MRNA ), a biotechnology company at the forefront of mRNA technology, is experiencing a significant surge in its stock price, climbing over 10% to surpass the $114 per share mark. This rally marks Moderna's highest level since January, reflecting a remarkable turnaround from its challenges in 2023. The resurgence of Moderna's stock can be attributed to several key factors that are igniting investor enthusiasm and confidence in the company's future prospects. One of the primary catalysts driving Moderna's stock rally is the initiation of a mid-stage clinical trial for its experimental cancer vaccine targeting cutaneous squamous cell carcinoma, a prevalent form of skin cancer. This groundbreaking trial, conducted in collaboration with Merck, underscores Moderna's commitment to pioneering innovative solutions in oncology. In addition to advancements in oncology, Moderna ( NASDAQ:MRNA ) continues to make significant strides in addressing infectious diseases, oncology, and rare diseases. Despite the challenges posed by the endemic market, Moderna ( NASDAQ:MRNA ) reported notable pipeline advancements in its fourth-quarter results. The company anticipates initial regulatory approvals for its RSV vaccine (mRNA-1345) starting in the first half of 2024, further bolstering its position in the market. Moreover, Moderna ( NASDAQ:MRNA ) remains optimistic about its COVID-19 franchise, projecting profitability in anticipated sales scenarios for 2024 and beyond. With approximately $4 billion in product sales expected in 2024, primarily driven by COVID-19 vaccine sales and the launch of its RSV vaccine, Moderna is poised for robust growth in the coming years. Technical Analysis Shares of Moderna ( NASDAQ:MRNA ) is exhibiting a bullish Flag pattern indicating the NASDAQ:MRNA has reacted to the Promising Cancer Vaccine Trials news. With a moderate Relative Strength Index (RSI) of 68.74 NASDAQ:MRNA shares is gaining momentum. Looking ahead, Moderna's pipeline update revealed a promising outlook, with 45 therapeutic and vaccine programs, nine of which are in late-stage development. Notably, the Phase 3 trial of its combination vaccine against seasonal flu and COVID-19 has been fully enrolled, with data expected in 2024. These developments underscore Moderna's commitment to innovation and its potential to deliver groundbreaking therapies to address critical unmet medical needs. In conclusion, Moderna's recent stock rally reflects growing optimism and confidence in the company's innovative pipeline, particularly in the areas of oncology and infectious diseases. With promising clinical trials underway and a robust portfolio of vaccine candidates, Moderna is well-positioned to capitalize on emerging market opportunities and drive long-term value for investors. As the company continues to make strides in pioneering mRNA technology, investors can expect Moderna to remain at the forefront of medical innovation, potentially revolutionizing the treatment landscape for various diseases, including cancer.
NASDAQ:MRNALong
by DEXWireNews
Pharmaceutical Giants Stocks: Macro Fib SchematicsThe biggest pharma giants are easy to recognize. Johnson and Johnson, Pfizer, Moderna, Merck & Co, Danaher Corp, Thermo Fisher Scientific. All medications and pharmaceutical drugs come out of these drug corporations. Lab equipment, medical research, vaccines, and other life science developments come out of these conglomerate pharma giants. Support and Resistance is clear with these schematics. All clusters are laid over appropriately.
NASDAQ:MRNA
by MichaelBsul